arrow
C

Carlos Malvestutto

ohio state university medical center
H指数:21
被引数:2,083

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

REPRIEVE研究人群中的高血压患病率及控制情况:一项二次分析的结果

2026-08-200
OAAI
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial

艾滋病病毒感染者中高血压的患病率、危险因素及对心血管系统的影响:REPRIEVE试验的二次分析

2026-04-290
PRE
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

匹伐他汀对血脂的影响与主要不良心血管事件的关系:一项REPRIEVE次要分析

2026-04-020
OAAI
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

转换为整合酶抑制剂后的肥胖、糖尿病、高血压和主要不良心血管事件风险:一项基于REPRIEVE试验的靶向试验模拟研究

2026-03-270
PRE
Statin Effects on Pericoronary Adipose Tissue Density in People With HIV

他汀类药物对HIV感染者冠状动脉周围脂肪组织密度的影响

2025-12-010
OAAI
Statin-dependent and-independent pathways are associated with major adverse cardiovascular events in people with HIV

他汀依赖性和非依赖性通路与HIV感染者中的主要不良心血管事件相关。

2025-11-170
OAAI
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2

基于PCE、PREVENT和SCORE2对全球HIV感染者心血管疾病预防队列的风险评估

2025-11-011
OAAI
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis

抗逆转录病毒药物对REPRIEVE试验中主要不良心血管事件的影响:一项纵向队列分析

2025-06-040
PRE
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial

匹他伐他汀对HIV感染者表观遗传衰老生物标志物的影响:REPRIEVE试验的试点亚组研究

2025-06-013
PRE
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With Human Immunodeficiency Virus (HIV)

影响人类免疫缺陷病毒(HIV)感染者全球心血管疾病(CVD)预防队列中心血管事件风险的因素

2025-04-250
PRE
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025-04-010
OAAI
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial
2024-12-110
PRE
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention: A Randomized Trial

接受匹伐他汀与安慰剂预防心血管疾病的HIV感染者的糖尿病危险因素: 一项随机试验

2024-11-011
PRE
Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV
2024-10-100
OAAI
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function

匹伐他汀耐受性良好,对身体功能无不利影响

2024-08-191
PRE
Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV
2024-04-150
PRE
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV
2024-04-0115
OAAI
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial

HIV感染者潜在性不确定克隆造血的危险因素: REPRIEVE试验报告

2024-02-162
OAAI